Earnings, deals and disclosures from Japan's listed pharma & healthcare companies, in English.
Santen Pharmaceutical's Chongqing joint venture, in liquidation since 2024, will apply for bankruptcy with about ¥3.3bn of liabilities, but the company says a fully provisioned ¥2bn loan means no new loss.
Northern TK Venture has appealed to the Tokyo High Court after the district court threw out its entire ¥203.3 billion damages claim against Daiichi Sankyo over a blocked Fortis Healthcare tender offer, and the pharma company now says the earnings impact is under review rather than nil.
Shionogi's amended securities report lowers disclosed compensation for its senior directors to ¥642mn from ¥895mn, driven by a corrected fringe-benefit figure for foreign-national directors; the correction also revises a related-party pay note but leaves other financial-statement figures unchanged.
A Tokyo court dismissed every claim in Northern TK Venture's three-year suit against Daiichi Sankyo, including a demand that swelled from ¥20bn to ¥203.3bn over a blocked Fortis Healthcare tender offer, though an appeal remains possible.
Gotham City Research, which admits it is short Sumitomo Pharma's stock, has accused the drugmaker of hiding image-duplication problems in research behind a treatment developed with Kyoto University; the company calls the report one-sided and defends its approval data.
Sumitomo Pharma says a ¥164.5bn dividend from its Swiss unit and a jump in receivables were routine accounting, not the earnings-management scheme Gotham City Research alleged in an August 3 short-seller report.
The CHMP said Tavneos’ benefits had not been shown to outweigh its risks after a review linked to phase III data-integrity concerns, leaving Kissei to assess Japan’s response and any earnings effect.